OncoSynergy Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 6

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $6.16M

  • Investors
  • 17

OncoSynergy General Information

Description

Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies employ a transformative strategy based on the RMI (Resistance Mechanism Inhibitors) principle that inhibits several cancer-driving pathways simultaneously, enabling oncologists to provide durable outcomes and cures for patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 850 Pacific Street
  • Unit 1802
  • Stamford, CT 06902
  • United States
+1 (415) 000-0000

OncoSynergy Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoSynergy Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 13-May-2022 $6.16M 000.00 Completed Clinical Trials - Phase 1
7. Later Stage VC 08-Sep-2020 00.000 000.00 Completed Clinical Trials - Phase 1
6. Grant 24-Jan-2020 000 000.00 Completed Clinical Trials - General
5. Later Stage VC (Series A) 14-May-2018 0000 000.00 0000 Completed Clinical Trials - General
4. Accelerator/Incubator 19-May-2017 000.00 Completed Clinical Trials - General
3. Accelerator/Incubator 000.00 Completed Clinical Trials - General
2. Merger/Acquisition 05-Apr-2016 Cancelled Clinical Trials - General
1. Equity Crowdfunding 28-Jun-2015 $13.2M $13.2M Completed Clinical Trials - General
To view OncoSynergy’s complete valuation and funding history, request access »

OncoSynergy Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view OncoSynergy’s complete cap table history, request access »

OncoSynergy Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel immunotherapies designed to improve outcomes for cancer patients. The company's immunotherapies emplo
Drug Discovery
Stamford, CT
6 As of 2022
000.00
0000000000 0 000.00

000000

por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Zurich, Switzerland
00 As of 0000
000.00
000000 0

000000

dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur si
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoSynergy Competitors (52)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Araris Biotech Venture Capital-Backed Zurich, Switzerland 00 000.00 000000 0
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000000 00000000 Venture Capital-Backed Schlieren, Switzerland 00 000.00 00000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 52 competitors. Get the full list »

OncoSynergy Patents

OncoSynergy Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018260887-A1 Anti- integrin beta1 antibody compositions and methods of use thereof Abandoned 26-Dec-2012 00000000000
EP-2938359-A4 Anti- integrin beta1 antibody compositions and methods of use thereof Withdrawn 26-Dec-2012 00000000000 0
JP-2016512487-A Anti-integrin β1 antibody composition and method of use Granted 26-Dec-2012 00000000000 0
EP-2938359-A1 Anti- integrin beta1 antibody compositions and methods of use thereof Withdrawn 26-Dec-2012 00000000000
US-20180312591-A1 Anti-integrin beta-1 antibody compositions and methods of use thereof Granted 26-Dec-2012 C07K16/2842
To view OncoSynergy’s complete patent history, request access »

OncoSynergy Executive Team (4)

Name Title Board Seat Contact Info
Anne-Marie Carbonell MD Co-Founder, Chief Executive Officer, President, Chief Medical Officer and Board Member
Ambar Picon Vice President, Corporate Operations
Gregory Wilson Consulting Chief Financial Officer
You’re viewing 3 of 4 executive team members. Get the full list »

OncoSynergy Board Members (5)

Name Representing Role Since
Allen Salmasi Ph.D Self Chairman 000 0000
Amanda Hayward Ph.D Connecticut Innovations Board Member 000 0000
Colin Foster Self Board Member 000 0000
Hen Park Ph.D OncoSynergy Board Member 000 0000
Robert Dunkle OncoSynergy Board Member 000 0000
To view OncoSynergy’s complete board members history, request access »

OncoSynergy Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoSynergy Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Cancer Institute Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Korea Information & Communications Company Corporation Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

OncoSynergy Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 01-May-2013 0000000000 Pharmaceuticals
To view OncoSynergy’s complete acquisitions history, request access »